Short Summary
Tecan Group AG files a Director Review request to overturn an institution decision that could invalidate its DNA‑sequencing patent, arguing the panel misapplied law, relied on unsupported expert testimony, and ignored PTAB policy on parallel petitions.
Detailed Summary
In a Request for Director Review, Tecan Group AG challenges the PTAB panel’s decision to institute an Inter Partes Review brought by Integrated DNA Technologies, Inc. Tecan contends the panel abused its discretion by misinterpreting claim language, relying on unsupported expert testimony from Dr. Peter Sims, and erroneously finding that the prior art (Kivioja) discloses all claim elements. The patent owner also argues that the institution decision conflicts with PTAB policy on parallel petitions and the proper application of discretionary denial under 35 U.S.C. § 325(d). Tecan seeks vacatur of the institution and denial of the petition.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Integrated DNA Technologies, Inc. et al. vs Tecan Group AG is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
AT&T Corp et al.vsDaingean Technologies Ltd.
Daingean Technologies Ltd. opposes AT&T and co‑petitioners' IPR petition on U.S. Patent 11,134,400, arguing the cited reference is not prior art and fails to teach the claimed SRB configurations, urging the Board to deny institution.
Shenzhen Tuozhu Technology Co., Ltd. et al.vsStratasys, Inc. et al.
Shenzhen Tuozhu Technology seeks a Director Review after the PTAB denied institution of its IPR against Stratasys’s 8,747,097 patent. The petitioner argues the denial violates statutory requirements and recent guidance on Sotera stipulations. The request highlights examiner error and lack of settled expectations by the patent owner.
Westinghouse Air Brake Technologies Corporation et al.vsRailware, Inc. et al.
Westinghouse (Wabtec) petitions the PTAB to invalidate Railware’s 9,517,782 patent covering a railway block‑release system, arguing the claims are obvious over public FRA reports and several secret‑code patents.
Cisco Systems, Inc.vsWSOU Investments LLC d/b/a Brazos Licensing and Development
Cisco has filed an IPR petition challenging claims 1 and 17 of WSOU’s U.S. 9,450,884 patent, asserting obviousness over multiple prior‑art references. The petition also argues that discretionary denial is inappropriate and requests institution of the review.
Guardant Health, Inc.vsCold Spring Harbor Laboratory
Guardant Health petitions the PTAB to invalidate Cold Spring Harbor Laboratory’s ’510 DNA‑sequencing patent, asserting that all challenged claims are obvious over the Lo application and other prior‑art references. The petition lists six grounds covering 30 claims and seeks cancellation of the entire patent.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.